A detailed history of Caxton Associates LP transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Caxton Associates LP holds 71,348 shares of VIR stock, worth $523,694. This represents 0.02% of its overall portfolio holdings.

Number of Shares
71,348
Previous 59,625 19.66%
Holding current value
$523,694
Previous $530,000 0.75%
% of portfolio
0.02%
Previous 0.02%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.26 - $10.7 $85,108 - $125,436
11,723 Added 19.66%
71,348 $534,000
Q2 2024

Aug 14, 2024

BUY
$7.63 - $12.66 $454,938 - $754,852
59,625 New
59,625 $530,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $974M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Caxton Associates LP Portfolio

Follow Caxton Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LP with notifications on news.